Eligibility criteria: Participants were male or female, 12 years of age or older, with mesial temporal lobe epilepsy (MTLE) and disabling seizures that persisted for no more than 2 years after failure of adequate trials of 2 brand-name antiepileptic drugs, one of which had to have had a monotherapy indication at the time of the study, who met criteria for anteromesial temporal resection. Brandname drugs were specified because generic substitution of antiepileptic drugs is not recommended by the American Academy of Neurology. 1 Specific drugs accepted for monotherapy and polytherapy have been published elsewhere. 2 Seizure persistence was defined as having (1) on average, at least one day every 2 months when at least one seizure occurred and (2) no intervals > 6 months between seizures during the 2 years prior to enrollment. Disabling seizures were defined as seizures that resulted in loss of awareness or that otherwise interfered with the ability to carry out usual activities, or were noticeable by others. Exclusion criteria included a history of serious cerebral insult after the age of 5, a progressive neurological disorder, psychogenic nonepileptic seizures, focal neurologic deficits other than memory disturbances, > 4 secondarily generalized seizures per year for > 3 years, or more than one episode of status epilepticus other than febrile status epilepticus. The latter 2 exclusionary criteria were felt to stretch the definition of "early". Surgical candidacy was determined by a standardized diagnostic protocol consisting of inpatient video-EEG monitoring, structural MRI, FDG-PET, and neurosychological and neuropsychiatric evaluations. 2 All participants randomized to surgery also underwent a bilateral intracarotid amobarbital procedure.
Seizure logs/diaries: Participants began recording seizure activity during the screening process. They were asked to record all seizure activity daily on a calendar. Participants provided a description their auras, their seizure activity, and any post-ictal symptoms they experienced. In addition, they were asked if the seizure interfered with their activity or was noted by others. Diaries were reviewed with the study staff at each visit. During the screening period, the seizures were classified by a blinded central seizure adjudication committee and any new types of seizure activity were similarly classified throughout the study.
Randomization: Participants were randomly assigned to the two treatment groups according to a computer-generated randomization plan that included stratification by center, age (12-16 vs. ≥ 17) , and side of ictal onset. It also included blocking within each stratum. The randomization plan was prepared by a programmer in the Biostatistics Center (Rochester, NY) whose only other involvement in the trial was to prepare reports for the independent Data and Safety Monitoring Board (DSMB). No other study personnel had access to treatment assignments prior to the enrollment of a participant. The randomization was implemented centrally at the Clinical Trials Coordination Center (CTCC; Rochester, NY). The site coordinator called the CTCC within 60 days of the initial consent to obtain the treatment assignment for the participant.
Cognitive assessment: Declines in memory and word-finding are common side effects of MTLE. 3 Cognitive function also may decline in medically-treated patients with persisting seizures, albeit more slowly. 4 We hypothesized that surgery would have a more modest effect that was limited to memory in this sample with established medial temporal lobe dysfunction, compared to the effect of persisting seizures and medication side effects on memory and other cognitive domains (attention and motor speed).
Participants completed a brief battery of neuropsychological tests prior to randomization and at 12 and 24 months following randomization. Cognitive domains assessed included visual attention (Trail Making Test, parts A & B (TMT)) 5 , auditory attention (WAIS-III Digit Span) 6 , motor speed/dexterity (Grooved Pegboard) 5 , verbal episodic and semantic memory (Rey Auditory Verbal Learning Test (RAVLT) 5 , WMS-R Logical Memory 7 , and Boston Naming Test 8 ) and visuospatial memory (Brief Visuospatial Memory Test -Revised (BVMT-R) 9 ). All of the neuropsychological tests yield continuous outcome measures with higher scores indicating better performance, except for Trail Making A, Trail Making B, and Grooved Pegboard for which lower scores indicate better performance.
Statistical Analysis:
Sample Size Determination: A sample size of 200 participants was planned to provide > 90% power to detect a group difference of 80% (surgical group) vs. 50% (medical group) in the percentage of participants free of disabling seizures in the second year of follow-up using a χ 2 -test and a significance level of 5%. It also provided between 80% and 90% power to detect group differences between 11 and 12 points 10 in terms of mean response on the QOLIE-89 overall raw score in adult participants using a t-test and a two-tailed 5% significance level, assuming a standard deviation of approximately 20 points. 11, 12 The calculations assumed the following: (1) 5% of the participants assigned to the surgical group would refuse surgical treatment or fail the intracarotid amobarbital procedure; (2) 10% of participants assigned to the medical group would ultimately receive surgical treatment prior to the end of the two-year follow-up; (3) 85% of participants would be adults (and thus included in the quality of life analysis); and (4) 10% of participants would not contribute quality-of-life data at two years. Further details are provided elsewhere. 2 
Primary outcome variable:
The primary statistical analyses were performed in accordance with the intention-to-treat principle and included all available data from all randomized participants. Due to the premature halting of the trial, some of the original plans for statistical analysis were modified. All modifications, however, were made prior to database lock. One modification was to change the analysis of the primary outcome variable to use Fisher's exact text to compare the treatment groups rather than the originally planned logistic regression model that included treatment group, center, age group, and side of ictal onset. 2 The reason for the change was the small sample size (38 participants instead of the planned 200 participants) and relatively small total number of successful (seizure-free) outcomes (11) , and the belief that the original model would incorporate too many parameters in this context (for example, there were 17 centers and only 2 subjects enrolled in the adolescent age group). For the primary analysis, participants who did not have complete follow-up during Year 2 were considered to not be seizure-free. The analyses were repeated after omitting participants who did not have complete follow-up during Year 2, unless they had reported seizures in Year 2.
In addition to the above analyses, a sensitivity analysis using multiple imputation was performed. 13 The imputation model was a logistic regression model that included treatment group, age (continuous), gender, and side of ictal onset as independent variables and the primary outcome variable as the dependent variable. Due to the sparse nature of the data, an exact logistic regression model was fit using Firth's penalized likelihood approach that eliminates the first-order bias of the parameter estimates and also avoids infinite parameter estimates.
14 For each of the 6 subjects with missing data for the primary outcome variable, the predicted probability of seizure freedom π was computed for the subject from the fitted logistic regression model and the missing datum was imputed by randomly assigning a value of 1 (seizure freedom) with probability π or assigning a value of 0 (no seizure freedom) with probability 1 -π . This yielded a complete data set, which was then analyzed using exact penalized logistic regression 14 with treatment group as the sole independent variable. This process was repeated 100 times, yielding 100 complete data sets and corresponding parameter estimates (odds ratios) and standard errors. These were combined across the multiple imputed data sets using standard methods 13 yielding an overall estimated odds ratio and corresponding 95% confidence interval and p-value.
Quality of life:
For continuous outcome variables that were approximately normally distributed (QOLIE-89 scores), repeated measures analysis of covariance models were used to estimate treatment effects (surgical -medical) at each time point, with effects at Month 24 being of primary interest. The model included terms for treatment group, month (categorical variable), and the interaction between treatment group and month, with side of ictal onset and the baseline value of the outcome variable also included as covariates. Contrary to the original plan for analysis 2 , it was decided a priori to omit center from the model due to the small number of participants enrolled (38) relative to the number of enrolling centers (17) . The within-subject covariance matrix was modeled as unstructured. Treatment effects are summarized using differences between adjusted group mean responses and their associated 95% confidence intervals. All available data from all adult (age ≥ 17) participants were included in the analyses. Secondary analyses were performed that omitted data obtained after the time of surgery for participants in the medical group who had surgery prior to the Month 24 visit. In these analyses, the repeated measures analysis of covariance model used maximum likelihood to estimate the parameters of interest (treatment effects) using available data from all (adult) participants. The model thus accommodated missing data in a reasonable manner under the missing at random assumption. 15 Ancillary outcomes: Categorical ancillary outcomes such as employment or educational status and driving status were compared between treatment groups using Fisher's exact tests. The distributions of other ancillary outcomes such as number of hours per week worked, number of sick days in the past 3 months, number of hospitalizations in the past 3 months, and number of days per month socializing with family or friends were compared between treatment groups using Wilcoxon rank sum tests, with treatment effects and associated confidence intervals based on the HodgesLehmann estimate. Outcomes measured at Month 24 were of primary interest.
Cognitive function: For the primary analysis, neuropsychological tests were divided into memory (RAVLT Delayed Recall, Boston Naming Test, WMS-R Logical Memory -Delayed Recall, BVMT-R Delayed Recall) and non-memory domains (Grooved Pegboard [average of dominant and non-dominant hands], TMT Part A, TMT Part B, Digit Span), with the primary focus being on the memory domain. For each domain, the treatment groups were compared using O'Brien's nonparametric global multivariate test. 16 This test is sensitive to treatment effects that are consistent across the multiple measures within a domain and does not depend on the assumption of multivariate normality. The primary analyses of cognitive function were performed using data at Month 24.
Missing values for O'Brien's test were imputed using regression-based imputation. For participants with complete data up to a particular visit (starting with Month 12), a regression model was fitted with that visit's outcome as the dependent variable and treatment group, age, gender, side of ictal onset, and the outcomes at previous visits (possibly imputed at a previous step) as independent variables. For participants with a missing value for all outcomes within a domain (e.g., memory) at that visit, the predicted value for that participant based on the regression model was imputed. If a participant had data for some, but not all, of the outcomes within a domain (e.g., memory) at a particular visit, missing values were imputed based on regression models constructed using information from participants with complete data from that domain at that visit. These models included treatment group, age, gender, side of ictal onset, and all other available outcomes at that visit in the same cognitive domain.
Secondary analyses were performed to compare treatment groups regarding individual neuropsychological test results using repeated measures analysis of covariance models similar to those described above for the quality of life data, except that age and gender were included as additional covariates in the models. As in the analysis of the quality of life data, all available data from all randomized participants were used in the analysis; missing data were not imputed but were accommodated in a reasonable manner in the estimation of treatment effects via maximum likelihood.
Fisher's exact tests were used to compare the treatment groups with respect to the percentage of participants who had a "statistically reliable" decline in individual neuropsychological test performance at Month 12. A "statistically reliable" decline was defined using standardized regression-based reliable change indices. 17, 18 All formal analyses of neuropsychological test results excluded information from the two adolescents enrolled in the study since they were evaluated using different (child) versions of the tests. Also, these analyses omitted data obtained after the time of surgery for participants in the medical group who had surgery prior to the Month 24 visit. The Trail Making Test scores were logtransformed prior to statistical analysis.
Results:
Cognitive function: Baseline performance on the neuropsychological tests is summarized by treatment group in Table S1 . Performance in the two groups was generally comparable.
Multivariate outcomes in the memory and non-memory domains did not differ significantly between the surgical and medical groups at Table S2 describes the changes from baseline to Month 12 and 24 by treatment group for each of these domains. Participants in the surgical group tended to perform worse than those in the medical group regarding outcomes in the memory domain, particularly at 24 months. This was supported by the analyses of individual neuropsychological test results (Table S3) , which indicated nominally significant differences in favor of the medical group with regard to mean responses on the WMS-R Logical Memory Delayed Recall (p = 0.03) and Immediate Recall (p = 0.01) tests at Month 24. Mean response on the BVMT-R Delayed Recall also tended to be better in the medical group than in the surgical group at Month 24 (p = 0.06); the same was true of the Boston Naming Test at Months 12 (p = 0.08) and 24 (p = 0.18). No other treatment group differences were apparent at Month 24 or at Month 12 (Table S3) .
Larger percentages of participants in the surgical arm had a "statistically reliable" decline in performance on the RAVLT Delayed Recall (36% vs. 0%, p = 0.03) and the Boston Naming Test (55% vs. 7%, p = 0.02) at Month 12 (Table S4) . No other group differences were apparent with respect to "statistically reliable" declines.
Discussion:
The primary analyses of cognitive function outcomes did not reveal significant treatment group differences in either the memory domain or the non-memory domain, although performance tended to be worse in the surgical group than in the medical group in the memory domain, particularly at Month 24. The confidence intervals for the treatment effects on the individual neuropsychological tests are quite wide due to the small sample size, so the effect of treatment on cognitive outcomes would be best characterized as inconclusive rather than absent. The finding of generally worse performance on individual measures of verbal memory and retrieval in participants in the surgical group is consistent with the findings of many previous studies [19] [20] [21] , but some of these results may have occurred by chance given the number of outcome variables examined. 
